Jesse Gelsinger died after receiving a gene therapy treatment to treat a liver disease. The death sparked an investigation ...

Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of ...

Prominent critics say Sarepta’s Elevidys Duchenne therapy may overstate how much gene it delivers—raising new questions about ...

The first child to receive a new experimental gene therapy for a rare neurological disorder died a few days after dosing, the ...

A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain ...

Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene therapy ...

At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

Researchers in Berlin have used base editing to repair mutations that cause the kidney disorder ADPKD in cells from both mice ...

The medium, which is designed for high density perfusion culture, is available in a variety of media package options for continuous processing.

The first participant in an investigational gene therapy trial of STXBP1 encephalopathy died, Capsida Biotherapeutics said.

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s ...